Literature DB >> 23891973

Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis.

Yoshiro Itatani1, Kenji Kawada, Teruaki Fujishita, Fumihiko Kakizaki, Hideyo Hirai, Takuya Matsumoto, Masayoshi Iwamoto, Susumu Inamoto, Etsuro Hatano, Suguru Hasegawa, Taira Maekawa, Shinji Uemoto, Yoshiharu Sakai, Makoto Mark Taketo.   

Abstract

BACKGROUND & AIMS: Loss of the tumor suppressor SMAD4 correlates with progression of colorectal cancer (CRC). In mice, colon tumors that express CCL9 recruit CCR1(+) myeloid cells, which facilitate tumor invasion and metastasis by secreting matrix metalloproteinase 9.
METHODS: We used human CRC cell lines to investigate the ability of SMAD4 to regulate expression of CCL15, a human ortholog of mouse CCL9. We used immunohistochemistry to compare levels of CCL15 and other proteins in 141 samples of human liver metastases.
RESULTS: In human CRC cell lines, knockdown of SMAD4 increased CCL15 expression, and overexpression of SMAD4 decreased it. SMAD4 bound directly to the promoter region of the CCL15 gene to negatively regulate its expression; transforming growth factor-β increased binding of SMAD4 to the CCL15 promoter and transcriptional repression. In livers of nude mice, SMAD4-deficient human CRC cells up-regulated CCL15 to recruit CCR1(+) cells and promote metastasis. In human tumor samples, there was a strong inverse correlation between levels of CCL15 and SMAD4; metastases that expressed CCL15 contained 3-fold more CCR1(+) cells than those without CCL15. Patients with CCL15-expressing metastases had significantly shorter times of disease-free survival than those with CCL15-negative metastases. CCR1(+) cells in the metastases expressed the myeloid cell markers CD11b and myeloperoxidase, and also matrix metalloproteinase 9.
CONCLUSIONS: In human CRC cells, loss of SMAD4 leads to up-regulation of CCL15 expression. Human liver metastases that express CCL15 contain higher numbers CCR1(+) cells; patients with these metastases have shorter times of disease-free survival. Reagents designed to block CCL15 recruitment of CCR1(+) cells could prevent metastasis of CRC to liver.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BMDC; BMP; CRC; Carcinoma; Chemokine; Colon Cancer; DFS; MMP; SBE; Signal Transduction; Smad-binding element; TGF-β; TGF-β-inhibitory element; TIE; bone marrow-derived cell; bone morphogenetic proteins; colorectal cancer; disease-free survival; mCCL9; mRNA; matrix metalloproteinase; messenger RNA; mouse CCL9; siRNA; small interfering RNA; transforming growth factor-β

Mesh:

Substances:

Year:  2013        PMID: 23891973     DOI: 10.1053/j.gastro.2013.07.033

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  53 in total

Review 1.  Emerging cytokine networks in colorectal cancer.

Authors:  Nathan R West; Sarah McCuaig; Fanny Franchini; Fiona Powrie
Journal:  Nat Rev Immunol       Date:  2015-09-11       Impact factor: 53.106

Review 2.  Restoring TGFβ1 pathway-related microRNAs: possible impact in metastatic prostate cancer development.

Authors:  Juliana Inês Santos; Ana Luísa Teixeira; Francisca Dias; Mónica Gomes; Augusto Nogueira; Joana Assis; Rui Medeiros
Journal:  Tumour Biol       Date:  2014-04-25

3.  Prognostic impact of the combination of neutrophil-to-lymphocyte ratio and Glasgow prognostic score in colorectal cancer: a retrospective cohort study.

Authors:  Susumu Inamoto; Kenji Kawada; Ryosuke Okamura; Koya Hida; Yoshiharu Sakai
Journal:  Int J Colorectal Dis       Date:  2019-06-08       Impact factor: 2.571

Review 4.  Transforming Growth Factor β Superfamily Signaling in Development of Colorectal Cancer.

Authors:  Barbara Jung; Jonas J Staudacher; Daniel Beauchamp
Journal:  Gastroenterology       Date:  2016-10-20       Impact factor: 22.682

5.  Circulating inflammatory markers and colorectal cancer risk: A prospective case-cohort study in Japan.

Authors:  Minkyo Song; Shizuka Sasazuki; M Constanza Camargo; Taichi Shimazu; Hadrien Charvat; Taiki Yamaji; Norie Sawada; Troy J Kemp; Ruth M Pfeiffer; Allan Hildesheim; Ligia A Pinto; Charles S Rabkin; Shoichiro Tsugane
Journal:  Int J Cancer       Date:  2018-10-09       Impact factor: 7.396

6.  Conditional abrogation of transforming growth factor-β receptor 1 in PTEN-inactivated endometrium promotes endometrial cancer progression in mice.

Authors:  Yang Gao; Pengfei Lin; John P Lydon; Qinglei Li
Journal:  J Pathol       Date:  2017-08-07       Impact factor: 7.996

7.  SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma.

Authors:  P Y Hernanda; K Chen; A M Das; K Sideras; W Wang; J Li; W Cao; S J A Bots; L L Kodach; R A de Man; J N M Ijzermans; H L A Janssen; A P Stubbs; D Sprengers; M J Bruno; H J Metselaar; T L M ten Hagen; J Kwekkeboom; M P Peppelenbosch; Q Pan
Journal:  Oncogene       Date:  2014-12-22       Impact factor: 9.867

Review 8.  Tumor regulation of the tissue environment in the liver.

Authors:  Tobias Eggert; Tim F Greten
Journal:  Pharmacol Ther       Date:  2017-02-04       Impact factor: 12.310

9.  Smad4 inhibits cell migration via suppression of JNK activity in human pancreatic carcinoma PANC-1 cells.

Authors:  Xueying Zhang; Junxia Cao; Yujun Pei; Jiyan Zhang; Qingyang Wang
Journal:  Oncol Lett       Date:  2016-04-07       Impact factor: 2.967

10.  CCL15 overexpression predicts poor prognosis for hepatocellular carcinoma.

Authors:  YueGuo Li; Hai Peng Yu; Peng Zhang
Journal:  Hepatol Int       Date:  2015-12-07       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.